Chest
Chest Infections: Special FeaturesDevelopment of Drugs for Nontuberculous Mycobacterial Disease: Clinicians’ Interpretation of a US Food and Drug Administration Workshop
Section snippets
Current State of Diagnosis and Treatment of NTM-PD
The reader is referred to other sources for a more complete description of the epidemiology, risk factors, and treatment outcomes in NTM-PD.2 The diagnosis of NTM-PD is based on clinical symptoms, radiographic findings, and the identification of NTM in cultures of respiratory specimens. Signs and symptoms may be pulmonary (eg, persistent cough, sputum production, hemoptysis) or systemic (eg, fever, night sweats, weight loss, fatigue). Radiographic features include nodular or tree-in-bud
Development of Antibacterial Drugs for NTM: A Patient Perspective
Patient perspectives regarding treatment of NTM-PD have been obtained from a number of sources. An NTM Research Consortium Workshop engaged patients to define research priorities and features of study design.11 The priorities identified with respect to treatment of infection included promoting quality-of-life measures for assessing the effectiveness of treatment and a need to reduce the burden of antibiotic treatment. Prior to this workshop, NTM Info & Research, a non-profit US organization
Development of Antibacterial Drugs for NTM: A Regulatory Perspective
The FDA mandate for development of new drugs is the demonstration of sufficient safety and efficacy, the latter defined as improving how a patient feels, functions, and/or survives. Accelerated approval of a drug was recently granted based on sputum culture conversion, but there are limited data evaluating the relationship between this microbiologic end point and clinical benefits. A review of the literature was conducted to establish whether culture conversion could be used as a surrogate end
Patient Population Heterogeneity
Previous studies have included heterogeneous subject populations (Table 2), but subjects recruited for a study should have disease manifestations that have the potential to respond to the treatment; that is, disease that is neither so indolent nor far advanced that treatment effects would be difficult to measure. The underlying condition and comorbidities may be highly relevant in predicting a response to treatment; patients with cystic fibrosis were excluded from a Phase III study14 based on
Conclusions
The clinicians on the panel concluded that NTM-PD is a condition in great need of new treatment options. Considerable knowledge has accrued in the past several years that has clarified the challenges that must be addressed in trial designs. These include selection of appropriate candidate subjects for clinical trials as well as proper outcome measures. There will always be interest in the microbiologic end points, but there is a need to define a clinical outcome measure to be used in NTM
Acknowledgments
Financial/nonfinancial disclosures: The authors have reported to CHEST the following: P. A. F. reports grants and personal fees from Insmed, Savara Pharmaceuticals, and the Cystic Fibrosis Foundation; grants from Novoteris; and personal fees from Janssen Research & Development and from Merck, outside of the submitted work. D. E. G. reports grants, personal fees, and nonfinancial support from Insmed Inc.; and personal fees from Spero, Merck, and Johnson & Johnson, outside of the submitted work.
References (22)
- et al.
Causes and imaging patterns of tree-in-bud opacities
Chest
(2013) - et al.
Microbiologic outcome of interventions against mycobacterium avium complex pulmonary disease: a systematic review
Chest
(2018) - et al.
Macrolide/azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease
Chest
(2014) - et al.
Time to detection of mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis
Chest
(1998) - et al.
Increasing prevalence rate of nontuberculous mycobacteria infections in five states, 2008-2013
Ann Am Thorac Soc
(2016) - et al.
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
Am J Respir Crit Care Med
(2007) - et al.
Relapse versus reinfection of mycobacterium avium complex pulmonary disease. Patient characteristics and macrolide susceptibility
Ann Am Thorac Soc
(2016) - et al.
Outcomes of mycobacterium avium complex lung disease based on clinical phenotype
Eur Respir J
(2017) - et al.
Semiquantitative culture analysis during therapy for mycobacterium avium complex lung disease
Am J Respir Crit Care Med
(2015) - et al.
Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease
Am J Respir Crit Care Med
(2017)
Intermittent antibiotic therapy for recurrent nodular bronchiectatic mycobacterium avium complex lung disease
Antimicrob Agents Chemother
Cited by (0)
FUNDING/SUPPORT: This publication was supported in part by the Intramural Research Program of the National Heart, Lung, and Blood Institute/National Institutes of Health and in part by the National Center for Advancing Translational Sciences of the National Institutes of Health [Grant UL1 TR001450].